Seitz: 'Context' of FDA Ratings Key in Medical Device Company's Derivative Case
The complaint, defense counsel argued, failed to show directors exhibited the state of mind needed for shareholders to proceed with their breach of fiduciary duty and related insider trading claims.
4 minute read